Study Reveals Dramatic Rise in Community-Acquired MRSA Infections
Posted on: Wednesday, 8 March 2006, 06:00 CST
A new study from Emory University School of Medicine and Grady Memorial Hospital has reported on a dramatic rise in antibiotic resistant community-acquired methicillin-resistant Staphylococcus aureus (MRSA), making it the primary cause of skin and soft tissue infections.
The bacterium Staphyloccus aureus (staph) normally resides on skin and in noses, and typically infects tissues through cuts or rashes. Those infections can remain minor, or lead to illnesses ranging from boils or abscesses to necrotizing skin infections, pneumonia and sometimes bloodstream infections.
Previously, scientists have categorized staph into two main types: antibiotic resistant (MRSA), and methicillin-susceptible Staphyloccus aureus (MSSA), which can be treated by antibiotics in the penicillin or related groups. Previously, MRSA infections were usually restricted to hospital or healthcare-associated infections. This is clearly no longer the case.
"We have seen an explosion of community-acquired MRSA infections among the urban patient populations served by the Grady Health System," noted Dr Henry Blumberg, senior author of the study and professor of medicine and program director of the division of infectious diseases at Emory University School of Medicine. "Community-acquired MRSA infections are no longer restricted to certain risk groups but appear to be widespread in the Atlanta community."
The study demonstrated that 72% of community-onset Staph skin and soft tissue infections among patients receiving care at the Grady Health System (Grady Memorial Hospital and its affiliated outpatient clinics in Atlanta) are now due to MRSA. The vast majority of these MRSA skin and soft tissue infections are due to a single clone or strain of MRSA called USA300.
The report authors say, "Empirical use of antibiotics active against community-acquired MRSA is warranted, especially for patients presenting with serious skin and soft-tissue infections." This represents a major change in prescribing practices for community-onset skin and soft tissue infections.
Dr Blumberg and his fellow researchers are now conducting follow-up studies at Grady Memorial Hospital and in the community, and hope other scientists might implement clinical trials to definitively determine which antibiotic agents work best for the treatment of community acquired MRSA infections.
Source: Datamonitor
Related Articles
- Rise in Skin Infections, MRSA Suspected
- Accounting For the Majority of Nosocomial Infections, MRSA Is the Most Popular Target for Antibody Development
- Theravance Announces Acceptance of Telavancin MAA for the Treatment of Complicated Skin and Soft Tissue Infections in Europe
- Astellas and Theravance Announce Submission of Telavancin MAA for the Treatment of Complicated Skin and Soft Tissue Infections in Europe
- Landmark Communications, Inc. Acquires Franchise.Com Media Company to Grow Franchise Information Portal
- TelePacific Communications to Acquire Arrival Communications
- Shaw Communications to Acquire Grand Forks Cable Systems
- Pacer Health Corporation Signs LOI to Acquire Interest in Louisiana Hospital; Group of Physician Investors Selects Pacer Health As Management and Equity Partner
- Staphylococcus Aureus Pneumonia: A "Superbug" Infection in Community and Hospital Settings
- MRSA Victim Calls for Matrons to Lead Hospital Clean-Up
User Comments (0)

RSS Feeds